title: Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.
abstract: Neuropathic pain is a large unmet medical need. The angiotensin II type 2 (AT2 ) receptor is a target with promising data in rodent models of peripheral neuropathic pain. The AT2 receptor has attracted attention on the basis of human data from a proof-of-concept clinical trial showing that oral EMA401, a highly selective, peripherally restricted, small molecule AT2 receptor antagonist, at 100 mg twice-daily for 4 weeks, alleviated postherpetic neuralgia, an often intractable type of peripheral neuropathic pain.
authors: Department of Surgery and Cancer, Imperial College London, London, SW10 9NH, UK.
authors: A S C
authors: AS
authors: Rice
authors: M T
authors: MT
authors: Smith
mesh_terms: D000804:Angiotensin II / Q000502:physiology; D057912:Angiotensin II Type 2 Receptor Blockers / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use; D008959:Models, Neurological; D058990:Molecular Targeted Therapy; D009437:Neuralgia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D044139:Receptor, Angiotensin, Type 2 / Q000378:metabolism*; D015203:Reproducibility of Results
chemical_list: D057912:Angiotensin II Type 2 Receptor Blockers; D001559:Benzhydryl Compounds; C000595242:EMA400; D007546:Isoquinolines; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II